Categories
Anthem Biosciences Limited — Updates, 19-05-2026: Press Release
19-05-2026 · 08:17 pm
Anthem Biosciences posted robust FY26 results. FY26 revenue grew 15.2% to ₹2,124.3 Cr, with PAT up 31.1% to ₹591.8 Cr. Q4 revenue jumped 26.4% to ₹610.9 Cr, and PAT surged 129.8% to ₹189.8 Cr. Strong CRDMO performance.
No comments yet. Be the first to comment!